Montreal, Quebec (March 18, 2021) – Emovi, Inc., a medical device company developing products for knee joint assessment, today announced that Eule Glenn has joined the company as Vice President of Business Development. In this role, Glenn will be responsible for the KneeKGTM system’s roll-out throughout the United States, and in conjunction with the Emovi leadership team, he will support the acceleration of the organization’s vision to transform the treatment and prevention of knee pain and injuries.
Eule brings to Emovi more than 15 years of experience in medical sales. He is a skilled senior leader with an extensive background, initiating and closing sales opportunities, accelerating growth, and driving profitability. He joins Emovi from Results Physiotherapy, where he was instrumental in supporting the business as it expanded by 300% from 60 to 185 clinics. Eule was responsible for and led efforts in recruiting, hiring, and training new sales team members. He also worked in a highly collaborative fashion with the operational leaders and internal marketing team to develop strategy, budget, and success of the Results brand. Prior to Results Physiotherapy, Glenn worked with Eli Lilly and Company for eight years as a Senior Sales Representative. Glenn holds his bachelor’s degree from the University of Alabama.
“In my career, I have been fortunate to participate in advancing patient care by educating and providing health care professionals with the tools they need to deliver exceptional patient care,” noted Glenn. “The KneeKG is precisely such a tool, providing doctors with technical information that has a higher correlation to symptoms and at a fraction of the cost of high-tech scans such as MRIs. The KneeKG allows healthcare professionals to significantly improve patients’ quality of life while reducing pain and functional limitations, and I am excited to join Emovi and look forward to working with the team to bring the KneeKG system into more U.S. clinics.”
Tapping into deep industry roots, Emovi also welcomes Adam Carter, PT, Margaret Davidson, Scott Marshall, and Jená Rutter, PT as business development consultants.
Adam Carter joins Emovi with over 20 years of practicing Physiotherapy. Based in Nashville, Tennessee, Carter is a manual therapist with a robust clinical skill set, specializing in treating sports injuries, back and neck pain, and postural dysfunction. His previous roles include clinic owner and director, and he is an active contributor to the Belmont School of Physical Therapy and Meharry Medical College. Carter received his degree in Physiotherapy from the University of South Australia.
Margaret Davidson is an award-winning sales producer with 14 years of achievement in the medical industry and six years of leadership in NCAA Division 1 athletics. Her passion for helping patients live pain-free has translated into proven success in negotiating sales, developing top performers, and consistently exceeding market share and volume goals. Davidson received her degree in Communications from Wake Forest University.
Scott Marshall brings over 15 years of successful marketing, business management, and business analytics in the healthcare industry. He has worked within both the pharmaceutical and physical therapy industry, where he utilized his expertise in building strategic client relationships to expand regional and national market share. Scott holds a B.S. in Marketing from The University of Tennessee.
Jená Rutter has spent the past 15 years in acute care inpatient therapy with a primary focus on intensive care and trauma. Rutter’s deep dedication to her patients allowed them to maximize their independence with functional mobility while reducing or eliminating pain. She graduated with a Master’s in physical therapy from the College of Mount Saint Joseph.
“The diversity of skill sets and experience throughout the company is something we are very proud of, and I am pleased to welcome Eule, Adam, Margaret, Scott, and Jená to the Emovi team,” said Michelle Laflamme, Chief Executive Officer of Emovi. “They will each play an integral role in the overall accomplishments of Emovi, and I look forward to a long and successful future together.”
Continued Laflamme, “Having the ability to attract and hire individuals with the industry knowledge and pedigrees of Eule, Adam, Margaret, Scott, and Jená is a testament to how Emovi is perceived in the industry. Each of them brings a unique perspective and skillset to Emovi, and each will play an important role in furthering KneeKG™.”
Emovi’s KneeKG is a brief in-clinic exam that accurately and objectively assesses the knee’s movement in three dimensions (3D) while the athlete walks on a conventional treadmill. The computerized assessment based on A.I./Machine Learning provides valuable clinical data about the knee’s dynamic alignment and mechanical deficits. The KneeKGTM software extracts objective data to report new mechanical biomarkers related to knee pathologies and risk factors. In contrast to static information provided by X-ray and magnetic resonance imaging (MRI), KneeKG quickly identifies the biomechanical and functional deficits linked to pain and instabilities of an orthopedic cause, such as those associated with knee osteoarthritis, anterior knee pain, and ligament injuries. By providing a functional and objective knee assessment with a higher correlation to the symptoms, the KneeKG enables the clinician or trainer to develop a more focused treatment plan to significantly improve the athlete’s quality of life, pain, and functional limitations.
About Emovi Inc.
Headquartered in Montreal, Emovi is a medical device company that develops products for knee joint assessment to restore the patients’ quality of life. In partnership with the Quebec university research community, including the CRCHUM, École de Technologie supérieure (ÉTS), and TELUQ, Emovi completed the development of the KneeKG, a unique clinical tool evaluating knee functional deficiencies linked to patients’ symptoms and pathology progression. Emovi owns multiple patents and the exclusive worldwide license to commercialize KneeKG. https://emovi.ca
The KneeKG is FDA indicated for appropriate assessment of the 3D knee motion for patients who have impaired movement functions of an orthopedic cause. It is intended to provide information used for physical evaluation and treatment planning purposes.